Microbial Enantioselective Ester Hydrolysis for the Preparation of Optically Active 4,1-Benzoxazepine-3-acetic Acid Derivatives as Squalene Synthase Inhibitors

Microbial enantioselective ester hydrolysis for the preparation of optically active (3R, 5S)-(−)-5-phenyl-4,1-benzoxazepine-3-acetic acid derivatives as potent squalene synthase inhibitors was investigated. Pseudomonas diminuta and Pseudomonas taetrolens hydrolyzed the racemic ethyl ester of the 5-(...

Full description

Saved in:
Bibliographic Details
Published in:Chemical & pharmaceutical bulletin Vol. 50; no. 1; pp. 59 - 65
Main Authors: Tarui, Naoki, Nakahama, Kazuo, Nagano, Yoichi, Izawa, Motowo, Matsumoto, Kiyoharu, Kori, Masakuni, Nagata, Toshiaki, Miki, Takashi, Yukimasa, Hidefumi
Format: Journal Article
Language:English
Published: Tokyo The Pharmaceutical Society of Japan 2002
Maruzen
Japan Science and Technology Agency
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Microbial enantioselective ester hydrolysis for the preparation of optically active (3R, 5S)-(−)-5-phenyl-4,1-benzoxazepine-3-acetic acid derivatives as potent squalene synthase inhibitors was investigated. Pseudomonas diminuta and Pseudomonas taetrolens hydrolyzed the racemic ethyl ester of the 5-(2-chlorophenyl) analogue to yield the (−)-carboxylic acid with excellent enantiomeric excess (>99% ee). We found that the (−)-enantiomer was an active inhibitor. Bulkiness of the ester moiety did not affect the enantioselectivity but did affect reac-tivity. The racemic ethyl ester of the 5-(2-methoxyphenyl) analogue, 5-(2,3-dimethoxyphenyl) analogue and 5-(2,4-dimethoxyphenyl) analogue were also hydrolyzed with Pseudomonas taetrolens to afford enantiomerically pure (−)-carboxylic acids in large scale. As another route to (3R,5S)-(−)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid [(−)-1c], the earlier intermediate (−)-2-amino-5-chloro-α-(2,3-dimethoxyphenyl)benzyl alcohol [(−)-12] was successfully obtained by asymmetric hydrolysis of (±)-5-chloro-α-(2,3-dimethoxyphenyl)-2-pivaloylaminobenzyl acetate with Pseudomonas sp. S-13 with >99% ee in kilogram scale followed by alkaline treatment. The product (−)-12 was converted to (−)-1c without racemization.
AbstractList Microbial enantioselective ester hydrolysis for the preparation of optically active (3R,5S)-(-)-5-phenyl-4,1-benzoxazepine-3-acetic acid derivatives as potent squalene synthase inhibitors was investigated. Pseudomonas diminuta and Pseudomonas taetrolens hydrolyzed the racemic ethyl ester of the 5-(2-chlorophenyl) analogue to yield the (-)-carboxylic acid with excellent enantiomeric excess (>99% ee). We found that the (-)-enantiomer was an active inhibitor. Bulkiness of the ester moiety did not affect the enantioselectivity but did affect reactivity. The racemic ethyl ester of the 5-(2-methoxyphenyl) analogue, 5-(2,3-dimethoxyphenyl) analogue and 5-(2,4-dimethoxyphenyl) analogue were also hydrolyzed with Pseudomonas taetrolens to afford enantiomerically pure (-)-carboxylic acids in large scale. As another route to (3R,5S)-(-)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid [(-)-1c], the earlier intermediate (-)-2-amino-5-chloro-alpha-(2,3-dimethoxyphenyl)benzyl alcohol [(-)-12] was successfully obtained by asymmetric hydrolysis of (+/-)-5-chloro-alpha-(2,3-dimethoxyphenyl)-2-pivaloylaminobenzyl acetate with Pseudomonas sp. S-13 with >99% ee in kilogram scale followed by alkaline treatment. The product (-)-12 was converted to (-)-1c without racemization.
Microbial enantioselective ester hydrolysis for the preparation of optically active (3R,5S)-(-)-5-phenyl-4,1-benzoxazepine-3-acetic acid derivatives as potent squalene synthase inhibitors was investigated. Pseudomonas diminuta and Pseudomonas taetrolens hydrolyzed the racemic ethyl ester of the 5-(2-chlorophenyl) analogue to yield the (-)-carboxylic acid with excellent enantiomeric excess (>99% ee). We found that the (-)-enantiomer was an active inhibitor. Bulkiness of the ester moiety did not affect the enantioselectivity but did affect reactivity. The racemic ethyl ester of the 5-(2-methoxyphenyl) analogue, 5-(2,3-dimethoxyphenyl) analogue and 5-(2,4-dimethoxyphenyl) analogue were also hydrolyzed with Pseudomonas taetrolens to afford enantiomerically pure (-)-carboxylic acids in large scale. As another route to (3R,5S)-(-)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid [(-)-1c], the earlier intermediate (-)-2-amino-5-chloro-alpha-(2,3-dimethoxyphenyl)benzyl alcohol [(-)-12] was successfully obtained by asymmetric hydrolysis of (+/-)-5-chloro-alpha-(2,3-dimethoxyphenyl)-2-pivaloylaminobenzyl acetate with Pseudomonas sp. S-13 with >99% ee in kilogram scale followed by alkaline treatment. The product (-)-12 was converted to (-)-1c without racemization.
Microbial enantioselective ester hydrolysis for the preparation of optically active (3R, 5S)-(-)-5-phenyl-4,1-benzoxazepine-3-acetic acid derivatives as potent squalene synthase inhibitors was investigated. Pseudomonas diminuta and Pseudomonas taetrolens hydrolyzed the racemic ethyl ester of the 5-(2-chlorophenyl) analogue to yield the (-)-carboxylic acid with excellent enantiomeric excess (>99% ee). We found that the (-)-enantiomer was an active inhibitor. Bulkiness of the ester moiety did not affect the enantioselectivity but did affect reac-tivity. The racemic ethyl ester of the 5-(2-methoxyphenyl) analogue, 5-(2,3-dimethoxyphenyl) analogue and 5-(2,4-dimethoxyphenyl) analogue were also hydrolyzed with Pseudomonas taetrolens to afford enantiomerically pure (-)-carboxylic acids in large scale. As another route to (3R,5S)-(-)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid [(-)-1c], the earlier intermediate (-)-2-amino-5-chloro-α-(2,3-dimethoxyphenyl)benzyl alcohol [(-)-12] was successfully obtained by asymmetric hydrolysis of (±)-5-chloro-α-(2,3-dimethoxyphenyl)-2-pivaloylaminobenzyl acetate with Pseudomonas sp. S-13 with >99% ee in kilogram scale followed by alkaline treatment. The product (-)-12 was converted to (-)-1c without racemization.
Microbial enantioselective ester hydrolysis for the preparation of optically active (3R, 5S)-(−)-5-phenyl-4,1-benzoxazepine-3-acetic acid derivatives as potent squalene synthase inhibitors was investigated. Pseudomonas diminuta and Pseudomonas taetrolens hydrolyzed the racemic ethyl ester of the 5-(2-chlorophenyl) analogue to yield the (−)-carboxylic acid with excellent enantiomeric excess (>99% ee). We found that the (−)-enantiomer was an active inhibitor. Bulkiness of the ester moiety did not affect the enantioselectivity but did affect reac-tivity. The racemic ethyl ester of the 5-(2-methoxyphenyl) analogue, 5-(2,3-dimethoxyphenyl) analogue and 5-(2,4-dimethoxyphenyl) analogue were also hydrolyzed with Pseudomonas taetrolens to afford enantiomerically pure (−)-carboxylic acids in large scale. As another route to (3R,5S)-(−)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid [(−)-1c], the earlier intermediate (−)-2-amino-5-chloro-α-(2,3-dimethoxyphenyl)benzyl alcohol [(−)-12] was successfully obtained by asymmetric hydrolysis of (±)-5-chloro-α-(2,3-dimethoxyphenyl)-2-pivaloylaminobenzyl acetate with Pseudomonas sp. S-13 with >99% ee in kilogram scale followed by alkaline treatment. The product (−)-12 was converted to (−)-1c without racemization.
Author Nakahama, Kazuo
Yukimasa, Hidefumi
Izawa, Motowo
Tarui, Naoki
Miki, Takashi
Kori, Masakuni
Matsumoto, Kiyoharu
Nagata, Toshiaki
Nagano, Yoichi
Author_xml – sequence: 1
  fullname: Tarui, Naoki
  organization: Takeda Chemical Industries, Ltd., Pharmaceutical Research Division
– sequence: 2
  fullname: Nakahama, Kazuo
  organization: Takeda Chemical Industries, Ltd., Pharmaceutical Research Division
– sequence: 3
  fullname: Nagano, Yoichi
  organization: Takeda Chemical Industries, Ltd., Pharmaceutical Research Division
– sequence: 4
  fullname: Izawa, Motowo
  organization: Takeda Chemical Industries, Ltd., Pharmaceutical Research Division
– sequence: 5
  fullname: Matsumoto, Kiyoharu
  organization: Takeda Chemical Industries, Ltd., Pharmaceutical Research Division
– sequence: 6
  fullname: Kori, Masakuni
  organization: Takeda Chemical Industries, Ltd., Pharmaceutical Research Division
– sequence: 7
  fullname: Nagata, Toshiaki
  organization: Takeda Chemical Industries, Ltd., Pharmaceutical Production Division
– sequence: 8
  fullname: Miki, Takashi
  organization: Takeda Chemical Industries, Ltd., Pharmaceutical Research Division
– sequence: 9
  fullname: Yukimasa, Hidefumi
  organization: Takeda Chemical Industries, Ltd., Pharmaceutical Research Division
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13455364$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/11824586$$D View this record in MEDLINE/PubMed
BookMark eNpd0dFqFDEUBuAgFbutXvgCEhAFobMmk2Qmc1OodWsLlQrV6-FM5oybZTaZJrPF6cv4qmbZ1QUvklzky8nhPyfkyHmHhLzmbM5zqT-aoZkrNlfVMzLjQpaZynNxRGaMsSrLRSGOyUmMK8ZyxUrxghxzrnOpdDEjv79aE3xjoacLB260PmKPZrSPSBdxxECvpzb4foo20s4HOi6Rfgs4QICEHfUdvRtGa6DvJ3qxeyjPePYJ3ZP_BU84WIeZyMBgUknYln7GYB9hSyOFSO8fNtCjQ3o_uXEJEemNW9rGjj7El-R5B33EV_vzlPy4Wny_vM5u777cXF7cZkaJosoaLVRR5MCbAjGvUHMQ3HBWqVZoKaqubJXsKt10BpjURdvlafFOl6bUbVOKU_J-V3cI_mGDcazXNhrse3DoN7EuueRlUckE3_4HV34TXOqt5rJgIjGdJ_Vhp1K4MQbs6iHYNYSp5qzezqxOM6sVq1WV7Jt9xU2zxvYg90NK4N0eQEw5dwGcsfHghFQphG1r5zu3iiP8xH8AQkq-x79f8v1WHS6WEGp04g8gFrkJ
CODEN CPBTAL
CitedBy_id crossref_primary_10_1021_op2001673
crossref_primary_10_1002_chin_200229174
crossref_primary_10_1021_jm020234o
crossref_primary_10_1016_j_bmc_2004_08_033
Cites_doi 10.1016/0006-291X(86)90285-8
10.1248/cpb.50.53
10.1271/bbb.57.1334
10.1002/chin.199749337
10.1016/S0076-6879(85)10068-6
10.1021/cr00013a016
10.1002/chin.199549034
ContentType Journal Article
Copyright 2002 The Pharmaceutical Society of Japan
2002 INIST-CNRS
Copyright Japan Science and Technology Agency 2002
Copyright_xml – notice: 2002 The Pharmaceutical Society of Japan
– notice: 2002 INIST-CNRS
– notice: Copyright Japan Science and Technology Agency 2002
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TK
7TM
7U9
H94
7X8
DOI 10.1248/cpb.50.59
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Neurosciences Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
AIDS and Cancer Research Abstracts
Virology and AIDS Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
AIDS and Cancer Research Abstracts

Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1347-5223
EndPage 65
ExternalDocumentID 3133471571
10_1248_cpb_50_59
11824586
13455364
article_cpb_50_1_50_1_59_article_char_en
Genre Journal Article
GroupedDBID ---
.55
.GJ
29B
2WC
3O-
53G
5GY
6J9
AABQG
AAUGY
ABTAH
ACGFO
ACIWK
ACPRK
ADBBV
AENEX
AFRAH
AI.
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BKOMP
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
GX1
HH5
JMI
JSF
JSH
KQ8
L7B
MOJWN
OK1
P2P
RJT
RZJ
TKC
TR2
VH1
X7J
X7M
XSB
ZE2
ZGI
ZY4
ABMYL
AHPSJ
ANFDX
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TK
7TM
7U9
H94
7X8
ID FETCH-LOGICAL-c5369-b835662a1b6ee29e81a31c1095d38439f7d54f98bfca0486df26df1f87c78db73
ISSN 0009-2363
IngestDate Sat Aug 17 01:43:15 EDT 2024
Thu Oct 10 18:27:22 EDT 2024
Fri Aug 23 01:40:33 EDT 2024
Sat Sep 28 08:39:11 EDT 2024
Tue Mar 12 05:32:04 EDT 2024
Thu Aug 17 20:28:50 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Pseudomonadales
Enantioselectivity
Enzyme
Transferases
Lactam
Enzyme inhibitor
Screening test
Farnesyl-diphosphate farnesyltransferase
In vitro
Cholesterol
Pseudomonas taetrolens
Asymmetric synthesis
Carboxylic acid
Chlorine Organic compounds
Bicyclic compound
Bacteria
Pseudomonadaceae
Aromatic compound
Chemical synthesis
Enantiomer(-)
Antilipemic agent
Oxygen nitrogen heterocycle
Enzymatic reaction
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c5369-b835662a1b6ee29e81a31c1095d38439f7d54f98bfca0486df26df1f87c78db73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.jstage.jst.go.jp/article/cpb/50/1/50_1_59/_article/-char/en
PMID 11824586
PQID 1460341782
PQPubID 1996362
PageCount 7
ParticipantIDs proquest_miscellaneous_71417694
proquest_journals_1460341782
crossref_primary_10_1248_cpb_50_59
pubmed_primary_11824586
pascalfrancis_primary_13455364
jstage_primary_article_cpb_50_1_50_1_59_article_char_en
PublicationCentury 2000
PublicationDate 2002
2002-Jan
2002-00-00
20020101
PublicationDateYYYYMMDD 2002-01-01
PublicationDate_xml – year: 2002
  text: 2002
PublicationDecade 2000
PublicationPlace Tokyo
PublicationPlace_xml – name: Tokyo
– name: Japan
PublicationTitle Chemical & pharmaceutical bulletin
PublicationTitleAlternate Chem. Pharm. Bull.
PublicationYear 2002
Publisher The Pharmaceutical Society of Japan
Maruzen
Japan Science and Technology Agency
Publisher_xml – name: The Pharmaceutical Society of Japan
– name: Maruzen
– name: Japan Science and Technology Agency
References 2) Santaniello E., Ferraboschi P., Grisenti P., Manzocchi A., Chem. Rev., 92, 1071—1140 (1992); Mori K., Synlett, 1995, 1097—1109 (1995); Robert S. M., J. Chem. Soc., Perkin Trans. 1, 1998, 157—169 and 1999, 1—12; Whitesides G. M., Wong C.-H., Angew. Chem., Int. Ed. Engl., 24, 617—718 (1985), for review.
10) Yanase H., Arishima T., Kita K., Nagai J., Mizuno S., Takuma Y., Endo K., Kato N., Biosci. Biotech. Biochem., 57, 1334—1337 (1993).
14) Although optically active 2-amino-5-chloro-α-(2,3-dimethoxyphenyl)benzyl alcohol derivatives are valuable intermediates for the production of drugs and other chemicals, few reports are available on their synthesis: a) Oishi T., Akita H., Kato M., JP 03-22992 (1991) [Chem. Abstr., 115, 157162 (1991)]; b) Kato M., Sasahara K., Ochi K., Akita H., Oishi T., Chem. Pharm. Bull., 39, 2498—2501 (1991); c) Shieh W.-C., Cantrell W. R., Carlson J. A., Tetrahedron Lett., 36, 3797—3800 (1995); d) Nozaki K., Kobori K., Uemura T., Tsutsumi T., Takaya H., Hiyama T., Bull. Chem. Soc. Jpn., 72, 1109—1113 (1999); e) Sakaguchi T., Imai T., Miura T., Yamazaki T., Okada T., JP 09-235255 (1997) [Chem. Abstr., 127, 262513 (1997)].
3) Sakamoto K., Tsuzaki K., Shima M., JP 09308497 (1997), [Chem. Abstr., 128, 74400 (1997)].
4) Ozaki E., Uragaki T., JP 09059217 (1997), [Chem. Abstr., 126, 277200 (1997)].
12) The optical purities of the unreacted esters obtained simultaneously were not determined.
1) Part 4 in the series of studies on 4,1-benzoxazepine derivatives as squalene synthase inhibitors: a) Part 1: Miki T., Kori M., Fujishima A., Mabuchi H., Tozawa R., Nakamura M., Sugiyama Y., Yukimasa H., Bioorg. Med. Chem., 10, 385—400 (2002); b) Part 2: Miki T., Kori M., Mabuchi H., Banno H., Tozawa R., Nakamura M., Itokawa S., Sugiyama Y., Yukimasa H., ibid., 10, 401—414 (2002); c) Part 3: Miki T., Kori M., Tozawa R., Nakamura M., Sugiyama Y., Yukimasa H., Chem. Pharm. Bull., 50, 53—58 (2002).
9) Isshiki K., Nakashima T., Yoshioka T., Tsunekawa H., Adachi T., Ota T., WO 9405637 (1994), [Chem. Abstr., 121, 9161 (1994)].
13) Cohen L. H., Griffioen A. M., Wanders R. J. A., Van Roermund C. W. T., Huysmans C. M. G., Princen H. M. G., Biochem. Biophys. Res. Commun., 138, 335—341 (1986).
7) Davisson V. J., Woodside A. B., Poulter C. D., Methods Enzymol., 110, 130—144 (1985).
6) Miyadera A., Imura A., JP 08070887 (1996), [Chem. Abstr., 125, 56411 (1996)].
11) Nakahama K., Izawa M., Nagano Y., Tarui N., Matsumoto K., Kori M., Kanamaru T., Nagata T., JP 08205889 (1996) [Chem. Abstr., 125, 32076 (1996)].
5) Ozaki E., Uragaki T., JP 09059211 (1997), [Chem. Abstr., 126, 277199 (1997)].
7) Ozaki E., Uragaki T., Sakashita K., Ikemoto T., Kobayashi Y., Sakimae A., WO 9534525 (1995), [Chem. Abstr., 124, 260386 (1995)].
8) Isshiki K., Nakajima T., Terasawa T., Watanabe Y., Tanaka H., Yoshioka T., JP 06319593 (1994), [Chem. Abstr., 122, 131151 (1994)].
11
YANASE H (10) 1993; 57
12
14
Davisson V. J., Woodside A. B., Pou (15) 1985; 110
1
3
4
5
Cohen L. H., Griffioen A. M., Wande (13) 1986; 138
6
7
8
9
(2) 1992; 92
References_xml – ident: 3
– ident: 12
– ident: 11
– volume: 138
  start-page: 335
  issn: 0006-291X
  issue: 1
  year: 1986
  ident: 13
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/0006-291X(86)90285-8
  contributor:
    fullname: Cohen L. H., Griffioen A. M., Wande
– ident: 1
  doi: 10.1248/cpb.50.53
– ident: 14
– volume: 57
  start-page: 1334
  issn: 0916-8451
  issue: 8
  year: 1993
  ident: 10
  publication-title: Biosci. Biotech. Biochem.
  doi: 10.1271/bbb.57.1334
  contributor:
    fullname: YANASE H
– ident: 5
  doi: 10.1002/chin.199749337
– volume: 110
  start-page: 130
  issn: 0076-6879
  year: 1985
  ident: 15
  publication-title: Methods Enzymol.
  doi: 10.1016/S0076-6879(85)10068-6
  contributor:
    fullname: Davisson V. J., Woodside A. B., Pou
– volume: 92
  start-page: 1071
  issn: 0009-2665
  issue: 5
  year: 1992
  ident: 2
  publication-title: Chem. Rev.
  doi: 10.1021/cr00013a016
– ident: 6
– ident: 9
– ident: 7
  doi: 10.1002/chin.199549034
– ident: 8
– ident: 4
  doi: 10.1002/chin.199749337
SSID ssj0025073
Score 1.6729378
Snippet Microbial enantioselective ester hydrolysis for the preparation of optically active (3R, 5S)-(−)-5-phenyl-4,1-benzoxazepine-3-acetic acid derivatives as potent...
Microbial enantioselective ester hydrolysis for the preparation of optically active (3R,5S)-(-)-5-phenyl-4,1-benzoxazepine-3-acetic acid derivatives as potent...
Microbial enantioselective ester hydrolysis for the preparation of optically active (3R, 5S)-(-)-5-phenyl-4,1-benzoxazepine-3-acetic acid derivatives as potent...
SourceID proquest
crossref
pubmed
pascalfrancis
jstage
SourceType Aggregation Database
Index Database
Publisher
StartPage 59
SubjectTerms 4,1-benzoxazepine-3-acetic acid
Animals
asymmetric hydrolysis
Azepines - chemistry
Azepines - metabolism
Azepines - pharmacology
Biological and medical sciences
Biotechnology
Enzyme Inhibitors - chemistry
Enzyme Inhibitors - pharmacology
Esters
Farnesyl-Diphosphate Farnesyltransferase - antagonists & inhibitors
Fundamental and applied biological sciences. Psychology
Health. Pharmaceutical industry
Humans
Hydrolysis
hypocholestemic agent
Industrial applications and implications. Economical aspects
Liver - drug effects
Liver - enzymology
Male
Other active biomolecules
Production of active biomolecules
Pseudomonas - metabolism
Pseudomonas sp. S-13
Pseudomonas taetrolens
Rats
Rats, Sprague-Dawley
squalene synthase
Stereoisomerism
Structure-Activity Relationship
Tumor Cells, Cultured
Title Microbial Enantioselective Ester Hydrolysis for the Preparation of Optically Active 4,1-Benzoxazepine-3-acetic Acid Derivatives as Squalene Synthase Inhibitors
URI https://www.jstage.jst.go.jp/article/cpb/50/1/50_1_59/_article/-char/en
https://www.ncbi.nlm.nih.gov/pubmed/11824586
https://www.proquest.com/docview/1460341782
https://search.proquest.com/docview/71417694
Volume 50
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Chemical and Pharmaceutical Bulletin, 2002, Vol.50(1), pp.59-65
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1db9MwFLW6wQMSQnxTGMNCaC9tRvOdPEassGnqmKATiJfIiW01gOKoaYH2z_BXubYTpx2agAceGlWJEzc5p9f33tjnIvRCFq8ilAUW2H5meQGEOxGlHP54hHOSQxCSqyK278Ozj9HR2Bv3eq3oUbfvvyIN-wBruXL2H9A2F4Ud8B0why2gDtu_wn1SKGklePJMznEpRK0q3cgJQkoUYTBb0bnQQiTtFMNqzrQEuHYeRaUS3F9XSmkDTvQACNvKWLkWP8iaVeCZWq5FcqbUXvOCDijc2jelIV7LyjW1XKsJVlQKIixmMFAOinJWZIUs7bPpDhu5AknAaraVXs82hcFlbiF5d3GiBwTxpTBJ7OQ0OZavCdTMkPVSdAfeJGdv1QgjinxmTjj5lHxQrSdiIb6LraxHFx1PyHy5blbJtTY9thy3MZNMm3HXCyHE1iuZWzuvBW63-KyNdiNJrod_Xbnit4HF8eRiibzKDv3RYXvCpnj3pUHVTHWEn-L7buDtoGsO2EJZ3uHo5NTkBMAdN8X-5E004lfQ3UvT2ZbLdP0zRA1SDuJmRWpAg-v6K1cHSMpRmt5Gt5oIByeamndQj5V30cG5Bnc1xNNuxV89xAf4vBNPX91DPw1_8WX-YsVf3PEXA38x8Bdv8BcLjg1_seYv9oZXsRdL9uIN9mJS45a9uGUv7th7H128Hk9fHVtNERErh8ceWxmEGEHgEDsLGHNiFtnEtcEGxT51I_DGeUh9j8dRxnMi5Scpd-Bj8yjMw4hmofsA7ZaiZI8QtnM_CkPXy9yAerFNY5eHEO84PA-462Ssj563OKWV1opJZYwNYKYAZuqPUj_uo1AjaJo0pqJtYjebuDsAOIBp66P9Lci7PhqK9dFey4G0sUi1DO1H4KlCINBHz8xhGEPki0FSMrGs09CGBkEMF3iomdNd2o4cz4-Cx3_q-wm6oeokqeTkHtpdzJfsKdqp6XJfEf4XctX3lg
link.rule.ids 315,782,786,4030,27934,27935,27936
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Microbial+enantioselective+ester+hydrolysis+for+the+preparation+of+optically+active+4%2C1-benzoxazepine-3-acetic+acid+derivatives+as+squalene+synthase+inhibitors&rft.jtitle=Chemical+%26+pharmaceutical+bulletin&rft.au=TARUI%2C+Naoki&rft.au=NAKAHAMA%2C+Kazuo&rft.au=NAGANO%2C+Yoichi&rft.au=IZAWA%2C+Motowo&rft.date=2002&rft.pub=Maruzen&rft.issn=0009-2363&rft.eissn=1347-5223&rft.volume=50&rft.issue=1&rft.spage=59&rft.epage=65&rft_id=info:doi/10.1248%2Fcpb.50.59&rft.externalDBID=n%2Fa&rft.externalDocID=13455364
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-2363&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-2363&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-2363&client=summon